BIOPHARMA CREDIT PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.878 USD | +0.23% |
|
+0.23% | +4.52% |
| 04-24 | BioPharma Credit, Unit to Loan up to $100 Million Each to US-based Tarsus Pharmaceuticals | MT |
| 04-24 | BioPharma Credit to loan USD100 million to Tarsus Pharmaceuticals | AN |
| Sales 2022 | 218M 17.46B | Sales 2023 | 136M 10.87B | Capitalization | 1.09B 87.6B |
|---|---|---|---|---|---|
| Net income 2022 | 182M 14.57B | Net income 2023 | 108M 8.65B | EV / Sales 2022 | 5.19 x |
| Net cash position 2022 | 121M 9.65B | Net cash position 2023 | 135M 10.81B | EV / Sales 2023 | 7.07 x |
| P/E ratio 2022 |
7.11
x | P/E ratio 2023 |
10.1
x | Employees | - |
| Yield 2022 |
7.37% | Yield 2023 |
8.33% | Free-Float | 88.56% |
More Fundamentals
* Assessed data
More news
| 1 day | +0.23% | ||
| 1 week | +0.23% | ||
| Current month | +0.92% | ||
| 1 month | -2.23% | ||
| 3 months | -6.60% | ||
| 6 months | +5.28% | ||
| Current year | +4.52% |
1 week
0.87
0.88
1 month
0.870.90
Current year
0.850.94
1 year
0.810.97
3 years
0.811.05
5 years
0.701.07
10 years
0.701.13
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Investment Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Harry Hyman
CHM | Chairman | 67 | 26/02/17 |
Duncan Budge
BRD | Director/Board Member | 68 | - |
| Director/Board Member | - | 04/12/18 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 0.878 | +0.23% | 1,651,853 |
| 25/04/24 | 0.876 | -0.23% | 1,232,752 |
| 24/04/24 | 0.878 | +0.23% | 5,369,025 |
| 23/04/24 | 0.876 | 0.00% | 2,292,315 |
| 22/04/24 | 0.876 | 0.00% | 1,393,094 |
Delayed Quote London S.E., April 26, 2024 at 04:35 pm
More quotes
BioPharma Credit PLC is a United Kingdom-based closed-ended investment company. The principal activity of the Company is to invest in interest-bearing debt assets with a contractual right to future cash flows derived from royalties or sales of approved life sciences products. The Company's investment objective is to generate long-term shareholder returns, predominantly in the form of sustainable income distributions from exposure to the life sciences industry. The Company seeks to achieve its investment objective predominantly through direct or indirect exposure to debt assets, which include royalty investments, senior secured debt, unsecured debt and credit linked notes. Its diversified portfolio is primarily secured by cash flows derived from sales of approved life sciences products. The Company holds a majority of its investments through its financing subsidiary, BPCR Limited Partnership. Its investment manager is Pharmakon Advisors L.P.
Sector
Closed End Funds
Calendar
12/06/2024
- Annual General Meeting
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
0.878
Average target price
-
| 1st Jan change | Capi. | |
|---|---|---|
| +4.52% | 1.08B | |
| +3.74% | 12.61B | |
| +5.50% | 9.01B | |
| -3.20% | 5.41B | |
| +2.44% | 5.25B | |
| +5.63% | 5.19B | |
| +14.36% | 4.48B | |
| +16.67% | 4.44B | |
| +1.53% | 4B | |
| +1.56% | 3.75B |
- Stock Market
- Equities
- BPCP Stock
